
Chennai: Cadila Healthcare Ltd has received USFDA approval for hydroxychloroquine sulphate tabs in the strength of 200 mg.
The medicine falls under the DMARD (disease modifying anti-rheumatic drug) section, and is used in caring rheumatoid arthritis.
According to NDC Health, the sales of such pills in the US market in 2006 stood at $30 million.